"ALS/MND is a truly devastating disease. At the UK DRI, we are committed to finding new treatments and changing the lives of those affected now and in the future." Prof Bart De Strooper
Former UK DRI Director

1. Background

Amyotrophic Lateral Sclerosis (ALS), or Motor Neurone Disease (MND), is a fatal neurodegenerative condition that causes progressive weakness of the muscles due to the degeneration of motor neurones in the brain and spinal cord. The average age at onset is 60 years and death usually occurs three years after the first symptoms appear, due to respiratory failure. Although there are some treatments available that can slow the progression by a few months, those affected are in desperate need of more effective therapeutics that improve symptoms and extend life expectancy.

2. UK DRI priority

UK DRI is the country's leading research institute for neurodegenerative disease with world experts across the ALS/MND research spectrum. Discovery science is the engine that drives medical progress; translational research is the process by which we apply our basic science discoveries to the needs of patients; clinical research is how we test these approaches in patients.

3. Latest news

Boosting brain immune cell waste clearance could provide new drug target for MND
A new study, led by Prof Siddharthan Chandran and Prof Josef Priller (UK DRI at Edinburgh), has revealed that the essential waste clearance role within microglia, the brain’s resident immune cells, is impaired in motor neuron disease (MND). The study, published in Science Advances, provides a potential new target for future drug discovery.
Read more

Developing 3D stem cell models of motor neuron disease
In an exciting new project, Dr Bhuvaneish T Selvaraj, Emerging Leader at the UK DRI at Edinburgh, will investigate the mechanisms underlying motor neuron disease (MND) using cutting-edge human stem cell technology.
Read more

Research reveals new insights into disease mechanisms underlying ALS
A new study led by Prof. Giampietro Schiavo (UK DRI at UCL) has uncovered why certain types of motor neurons are differentially affected in amyotrophic lateral sclerosis (ALS). The findings, published in the journal Acta Neuropathologica Communications, could open up new avenues for drug discovery and treatments for this disease.
Read more

4. Meet the team

Adrian Isaacs

UK DRI Group Leader

Frontotemporal dementia and amyotrophic lateral sclerosis disease mechanisms

UCL, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Andrea Serio

UK DRI Group Leader

Engineering neuroscience to learn more about neurodegeneration

King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Bhuvaneish Selvaraj

UK DRI Emerging Leader

Mechanisms of selective vulnerability of motor neurons in amyotrophic lateral sclerosis

Edinburgh, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Chris Shaw

UK DRI Group Leader

Proteostatic mechanisms in FTD and ALS

King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Emma Clayton

UK DRI Emerging Leader

Synaptopathy in FTD/ALS- investigating presynaptic proteostasis using novel tools in novel models

King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Gabriel Balmus

UK DRI Group Leader

Identifying neuroprotective mechanisms against genomic instability accrual in ageing and neurodegeneration

Cambridge, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Giampietro Schiavo

UK DRI Group Leader

Restoring axonal transport deficits as a therapeutic strategy for neurodegenerative diseases

UCL, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Jernej Ule

UK DRI Centre Director

RNA networks in ALS/FTD

King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Marc-David Ruepp

UK DRI Group Leader

Altered RNA metabolism in neurodegeneration

King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Sarah Marzi

UK DRI Group Leader

Epigenetic regulation of environmental and genetic risk in neurodegenerative disease

King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Sarah Mizielinska

UK DRI Group Leader

Single molecule nucleocytoplasmic transport dynamics in FTD/ALS

King's College London, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI

Siddharthan Chandran

UK DRI Director

Dissecting macroglial-neuronal crosstalk in C9ORF72 FTD/ALS

Edinburgh, Amyotrophic Lateral Sclerosis (ALS) research at UK DRI, UCL, Core team

A disease focus